These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 10815883

  • 1. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H, Chi KN, Gleave ME.
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [Abstract] [Full Text] [Related]

  • 2. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 3. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 Jan 01; 60(1):170-6. PubMed ID: 10646870
    [Abstract] [Full Text] [Related]

  • 4. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H, Hara I, Kamidono S, Gleave ME.
    Clin Cancer Res; 2001 Dec 01; 7(12):4245-52. PubMed ID: 11751526
    [Abstract] [Full Text] [Related]

  • 5. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 01; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 6. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M.
    Cancer Res; 2004 Sep 15; 64(18):6595-602. PubMed ID: 15374973
    [Abstract] [Full Text] [Related]

  • 7. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
    Miyake H, Hara I, Kamidono S, Gleave ME, Eto H.
    Oncol Rep; 2003 Sep 15; 10(2):469-73. PubMed ID: 12579291
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE, Hoffmann J, Rogatsch H, Schäfer G, Zopf D, Bartsch G, Klocker H.
    Cancer Gene Ther; 2002 Feb 15; 9(2):117-25. PubMed ID: 11857028
    [Abstract] [Full Text] [Related]

  • 9. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 15; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 10. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME.
    Clin Cancer Res; 2008 Sep 15; 14(18):5769-77. PubMed ID: 18794086
    [Abstract] [Full Text] [Related]

  • 11. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H, Hara I, Gleave ME.
    Int J Urol; 2005 Sep 15; 12(9):785-94. PubMed ID: 16201973
    [Abstract] [Full Text] [Related]

  • 12. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
    Yamanaka K, Gleave M, Muramaki M, Hara I, Miyake H.
    Oncol Rep; 2005 May 15; 13(5):885-90. PubMed ID: 15809754
    [Abstract] [Full Text] [Related]

  • 13. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME.
    Int J Cancer; 2001 Mar 15; 91(6):846-50. PubMed ID: 11275990
    [Abstract] [Full Text] [Related]

  • 14. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H, Hara S, Arakawa S, Kamidono S, Hara I.
    Br J Cancer; 2001 Mar 23; 84(6):859-63. PubMed ID: 11259104
    [Abstract] [Full Text] [Related]

  • 15. Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
    Kikuno N, Moriyama-Gonda N, Yoshino T, Yoneda T, Urakami S, Terashima M, Yoshida M, Kishi H, Shigeno K, Shiina H, Igawa M.
    Cancer Res; 2004 Oct 15; 64(20):7526-32. PubMed ID: 15492279
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
    Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC.
    Clin Cancer Res; 2003 Jul 15; 9(7):2826-36. PubMed ID: 12855663
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME.
    Neoplasia; 2005 Feb 15; 7(2):171-9. PubMed ID: 15802022
    [Abstract] [Full Text] [Related]

  • 20. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME.
    Cancer Res; 2003 Jul 01; 63(13):3575-84. PubMed ID: 12839944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.